Soligenix Inc (NASDAQ:SNGX)
| 0.6992 Delayed Data As of May 26 |  -0.0103 / -1.45%Today’s Change | 0.65 Today|||52-Week Range 15.00 | -89.69% Year-to-Date |
| SECTOR Health Technology | INDUSTRY Pharmaceuticals: Major | MARKET CAP $5.8M |
Company Description
Soligenix, Inc. is a late-stage biopharmaceutical company, which engages in the development and commercialization of products to treat rare diseases. It operates through the Specialized BioTherapeutics and Public Health Solutions segments. The Specialized BioTherapeutics segment focuses on the development of a novel photodynamic therapy (SGX301) utilizing topical synthetic hypericin activated with safe visible fluorescent light for the treatment of cutaneous T-cell lymphoma. The Public Health Solutions segment consists of active development programs for RiVax, a ricin toxin vaccine candidate, and SGX943, a therapeutic candidate for antibiotic resistant and emerging infectious disease. The company was founded in 1987 and is headquartered Princeton, NJ.
Contact Information
Soligenix, Inc. 29 Emmons Drive Princeton New Jersey 08540-5919 |
Employees
Shareholders
| Mutual fund holders | 2.02% |
| Other institutional | 1.64% |
| Individual stakeholders | 0.87% |
Top Executives
| Christopher J. Schaber | Chairman, President & Chief Executive Officer |
| Jonathan L. Guarino | Chief Financial Officer, Secretary & Senior VP |
| Oreola Donini | Chief Scientific Officer & Senior Vice President |
| Richard C. Straube | Chief Medical Officer & Senior Vice President |
| Adam T. Rumage | VP-Regulatory Affairs & Project Management |
